Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma [0.03%]
诱导治疗早期失败对霍奇金淋巴瘤移植结局的影响分析
Yu-Sung Chang,Wan-Chen Hsieh,Hsueh-Mei Chang et al.
Yu-Sung Chang et al.
Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells [0.03%]
CARTITUDE-1研究的长期结果公布：CAR-T细胞有望实现多发性骨髓瘤的功能治愈
Teresa de Soto,Nour Moukalled,Mohamad Mohty
Teresa de Soto
Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition [0.03%]
关于CTIWP、NXTGEN-HIGHTECH、DARE-NL、T2EVOLVE和GoCART联盟的EBMT相关中心的病毒载体制造能力与差距的调查研究报告
Ganesh Ramesh,Zsolt Sebestyen,Anil Kumar Deshantri et al.
Ganesh Ramesh et al.
Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI) [0.03%]
新型简化的风险评估(CORE)评分的多中心验证及与造血细胞移植合并症指数(HCT-CI)互补能力的确认
Gunnar Weise,Christina Rautenberg,Alexander Denk et al.
Gunnar Weise et al.
Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy [0.03%]
基线18F-FDG PET/CT对复发或难治性多发性骨髓瘤患者接受BCMA CAR-T细胞治疗后毒副反应和疗效的预测价值
Pingnan Xiao,Xin Zhao,Linqin Wang et al.
Pingnan Xiao et al.
Patients with relapsed/refractory multiple myeloma (R/R MM) receiving chimeric antigen receptor (CAR) T-cell therapy are at high risk of toxicities, including cytokine release syndrome (CRS). The roles of positron emission-tomography comput...
Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link [0.03%]
学术生物制品生产UNITC网络中原料、试剂和耗材的保障：因为木桶效应
Ugo Chartral,Jeanne Galaine,Camille Giverne et al.
Ugo Chartral et al.
Academic autologous cell manufacturing offers key advantages, including cost-effectiveness, accessibility, and flexibility. However, the management of Raw Materials, Reagents, and Consumables (RMRCs) is essential for ensuring product purity...
Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes [0.03%]
供者淋巴细胞预处理的单倍体相合移植治疗镰状细胞病儿童患者的效果良好
Irtiza N Sheikh,Shaikha Alqahtani,Olayinka Okeleji et al.
Irtiza N Sheikh et al.
Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia [0.03%]
成人急性淋巴细胞白血病患者减低强度预处理联合全身照射治疗（TBRI 8Gy）的临床研究
Klaus Wethmar,Matthias Edinger,Kerstin Schäfer-Eckart et al.
Klaus Wethmar et al.
Total body irradiation (TBI) plus chemotherapy is commonly applied prior to allogeneic hematopoietic stem cell transplantation (SCT) for patients with acute lymphoblastic leukemia (ALL). Here, we retrospectively analyzed registry data from ...
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma [0.03%]
自体造血干细胞移植治疗多发性骨髓瘤的疗效分析
Oren Pasvolsky,Curtis Marcoux,Denái R Milton et al.
Oren Pasvolsky et al.
Autologous hematopoietic cell transplantation (autoHCT) remains a therapeutic option for multiple myeloma (MM) at relapse. We retrospectively analyzed 650 patients who underwent delayed (n = 335) or salvage (n = 315) autoHCT at a single cen...
Efficacy of eltrombopag for treatment of thrombocytopenia in the setting of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis [0.03%]
艾曲泊帕治疗allo-HSCT后血小板减少的疗效：系统评价和meta分析
Arni Kumar,Arin Singh,Tea Reljic et al.
Arni Kumar et al.
Thrombocytopenia following an allogeneic hematopoietic cell transplant (allo-HCT) is a potentially serious complication, and the efficacy of eltrombopag, a thrombopoietin receptor agonist, in this context is unclear due to inconsistent find...